June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Characterizing the Effect of Anti-VEGF Injection on Choroidal Neovascularization Using Optical Coherence Tomography Angiography
Author Affiliations & Notes
  • Nora Wael Muakkassa
    Ophthalmology, New England Eye Center/Tufts Medical Center, Boston, MA
  • Adam T Chin
    Ophthalmology, New England Eye Center/Tufts Medical Center, Boston, MA
  • Talisa de Carlo
    Ophthalmology, New England Eye Center/Tufts Medical Center, Boston, MA
  • Caroline R Baumal
    Ophthalmology, New England Eye Center/Tufts Medical Center, Boston, MA
  • Andre Witkin
    Ophthalmology, New England Eye Center/Tufts Medical Center, Boston, MA
  • Jay S Duker
    Ophthalmology, New England Eye Center/Tufts Medical Center, Boston, MA
  • Nadia K Waheed
    Ophthalmology, New England Eye Center/Tufts Medical Center, Boston, MA
  • Footnotes
    Commercial Relationships Nora Muakkassa, None; Adam Chin, None; Talisa de Carlo, None; Caroline Baumal, None; Andre Witkin, None; Jay Duker, Carl Zeiss Meditec Inc. (C), Carl Zeiss Meditec Inc. (F), EyeNetra (I), Hemera Biosciences Inc. (I), Ophthotech Corp (I), Optovue (C), Optovue (F); Nadia Waheed, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 3326. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Nora Wael Muakkassa, Adam T Chin, Talisa de Carlo, Caroline R Baumal, Andre Witkin, Jay S Duker, Nadia K Waheed; Characterizing the Effect of Anti-VEGF Injection on Choroidal Neovascularization Using Optical Coherence Tomography Angiography. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):3326.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To measure the change in size of choroidal neovascularization (CNV) in response to anti-vascular endothelial growth factor (VEGF) treatment measured using a spectral domain optical coherence tomography angiography (SD-OCTA) system.

Methods: Eight eyes from eight patients diagnosed with CNV who underwent OCTA pre and post-treatment with anti-VEGF agents were enrolled. One eye was treatment-naïve. Each eye was imaged prior to treatment and scanned at multiple follow up visits using the prototype AngioVue OCTA system applying a split-spectrum amplitude decorrelation angiography (SSADA) algorithm on a SD-OCT device (Optovue Inc, Fremont, CA). The system operated at 70,000 A-scans per second to acquire OCTA volumes of 304 x 304 A-scans. Orthogonal registration and merging of two consecutive image sets were used to obtain OCT angiograms. OCTA volumes were segmented into 30-50 micrometer-thick en-face segments demonstrating the dimensions of the CNV. Trained readers at the Boston Image Reading Center measured the greatest linear dimension and the area of the CNV in the pre-treatment and post-treatment images. The primary outcomes of the study were greatest linear dimension and area of the CNV. Secondary outcomes included the appearance of CNV (well-circumscribed versus poorly circumscribed), the presence of subretinal and/or intraretinal fluid on OCT B-scan, and visual acuity.

Results: Eight eyes of eight patients with CNV were scanned with the OCTA system. Ages ranged from 31 - 85 and included four males and four females. Etiology of CNV included age-related macular degeneration, multifocal choroiditis and central serous chorioretinopathy. 50 % of eyes had significant reduction in the length and area of the CNV after treatment as well as resolution of subretinal fluid. 25 % had no change in the size of the CNV and no change in amount of subretinal fluid present.

Conclusions: CNV size measured using OCTA may decrease after successful anti-VEGF treatment. No change in the size of the CNV may suggest resistance to anti-VEGF agents. Optical coherence tomography angiography may be a useful tool for monitoring and quantifying the response of choroidal neovascularization to treatment.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×